TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
TG Therapeutics (NASDAQ: TGTX) announced that Chairman and CEO Michael S. Weiss will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference, taking place December 2–4, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TG Therapeutics (NASDAQ: TGTX) announced that Chairman and CEO Michael S. Weiss will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference, taking place December 2–4, 2025.
The fireside chat is scheduled for Tuesday, December 2, 2025 at 12:30 PM ET. A live webcast will be available on the company’s Investors & Media Events page at http://ir.tgtherapeutics.com/events.
Details
News Market Reaction – TGTX
On Nov 28, the day this news came out, TGTX closed 0.45% below the previous close.
Data tracked by StockTitan Argus for the Nov 28 session.
Key Figures
- Conference edition
- 8th Annual
- Evercore Healthcare Conference iteration
- Conference dates
- December 2–4, 2025
- Evercore Healthcare Conference schedule
- Fireside chat time
- 12:30 PM ET
- TG Therapeutics session on December 2, 2025
Historical Context
-
Announcement of Evercore Healthcare Conference fireside chat webcast availability.
-
Ranked #27 on Deloitte Technology Fast 500 driven by BRIUMVI growth.
-
TD Cowen Immunology & Inflammation Summit fireside chat and webcast access.
-
Q3 2025 results with strong BRIUMVI revenue, raised 2025 guidance and buybacks.
-
Scheduling of Q3 2025 results call and webcast with 30‑day replay.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fireside chat scheduled for Tuesday, December 2, 2025 at 12:30 PM ET
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 8th Annual Evercore Healthcare Conference, which is taking place from December 2 - 4, 2025. The fireside chat is scheduled to take place on Tuesday, December 2, 2025, at 12:30 PM ET.
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.